Bellerophon Therapeutics Inc Quick Ratio (BLPH) starting from the third quarter 2023 to third quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Bellerophon Therapeutics inc  (NASDAQ: BLPH)

Bellerophon Therapeutics Inc's Quick Ratio

BLPH's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Bellerophon Therapeutics Inc's Cash & cash equivalent, this led to improvement in Bellerophon Therapeutics Inc's Quick Ratio to 4.88, above Bellerophon Therapeutics inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 224 other companies have achieved higher Quick Ratio than Bellerophon Therapeutics Inc in third quarter 2023. While Quick Ratio total ranking has improved so far during the Q3 2023 to 758, from total ranking in the second quarter 2023 at 908.

Explain Quick Ratio?
How much Cash & cash equivalents BLPH´s has?
What are BLPH´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BLPH Quick Ratio (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3
Y / Y Current Liabilities Change -82.24 % -40.7 % -55.12 % 6.91 % 1.01 %
Y / Y Cash & cash equivalent Change -61.69 % -36.15 % -22.51 % -70.49 % -59.33 %
Quick Ratio MRQ 4.88 3.31 6.24 1.36 2.26
BLPH's Total Ranking # 758 # 908 # 541 # 1686 # 974
Seq. Current Liabilities Change -71.53 % 29.34 % -53.75 % 4.29 % -4.96 %
Seq. Cash & cash equivalent Change -57.97 % -31.42 % 112.54 % -37.47 % -29.94 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 225
Healthcare Sector # 377
Overall Market # 758


Quick Ratio Statistics
High Average Low
12.86 4.55 1.28
(Mar 31 2015)   (Mar 31 2020)




Financial Statements
Bellerophon Therapeutics Inc's Current Liabilities $ 1 Millions Visit BLPH's Balance sheet
Bellerophon Therapeutics Inc's Cash & cash equivalent $ 4 Millions Visit BLPH's Balance sheet
Source of BLPH's Sales Visit BLPH's Sales by Geography


Cumulative Bellerophon Therapeutics Inc's Quick Ratio

BLPH's Quick Ratio for the trailling 12 Months

BLPH Quick Ratio

 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth -43.28 % -23.05 % -15.68 % -11.84 % -28.88 %
Y / Y Cash & cash equivalent TTM Growth -48.12 % -49.93 % -52.52 % -56.28 % -51.28 %
Quick Ratio TTM 3.16 2.78 2.77 2.59 3.45
Total Ranking TTM # 456 # 689 # 448 # 1434 # 3688
Seq. Current Liabilities TTM Growth -26.11 % -11.97 % -14.21 % 1.64 % 0.25 %
Seq. Cash & cash equivalent TTM Growth -15.96 % -11.78 % -8.1 % -23.86 % -18.89 %

Quick ratio ranking by company, industry and sector >> Back to BLPH Financial Strength Comparisons >> Go to Compare BLPH Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Bellerophon Therapeutics Inc's average Cash & cash equivalent, this led to increase in in Bellerophon Therapeutics Inc's Quick Ratio to 3.16, Quick Ratio remained below BLPH average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 224 other companies have achieved higher Quick Ratio than Bellerophon Therapeutics Inc. While Quick Ratio overall ranking has improved so far to 456, from total ranking during the twelve months ending second quarter 2023 at 689.

Explain Quick Ratio?
How much Cash & cash equivalents BLPH´s has?
What are BLPH´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 225
Healthcare Sector # 377
Within the Market # 456


trailing twelve months Quick Ratio Statistics
High Average Low
12.86 4.55 1.28
(Mar 31 2015)   (Mar 31 2020)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Dynavax Technologies Corporation  13.28 $ 720.416  Millions$ 54.264  Millions
Kezar Life Sciences Inc   13.09 $ 218.205  Millions$ 16.672  Millions
Rocket Pharmaceuticals Inc   13.06 $ 437.171  Millions$ 33.476  Millions
Briacell Therapeutics Corp   13.04 $ 13.646  Millions$ 1.047  Millions
Vistagen Therapeutics Inc   12.93 $ 37.608  Millions$ 2.910  Millions
Silo Pharma Inc  12.92 $ 8.771  Millions$ 0.679  Millions
Rallybio Corporation  12.91 $ 121.384  Millions$ 9.402  Millions
Io Biotech Inc   12.75 $ 165.501  Millions$ 12.985  Millions
Relmada Therapeutics Inc  12.62 $ 106.267  Millions$ 8.422  Millions
Prothena Corporation Public Limited Company  12.57 $ 670.897  Millions$ 53.370  Millions
Processa Pharmaceuticals Inc   12.51 $ 6.861  Millions$ 0.549  Millions
Compass Pathways Plc  12.36 $ 248.369  Millions$ 20.100  Millions
Biomea Fusion Inc   12.28 $ 199.090  Millions$ 16.210  Millions
Ligand Pharmaceuticals Incorporated  12.11 $ 190.502  Millions$ 15.727  Millions
Oric Pharmaceuticals Inc   12.00 $ 227.296  Millions$ 18.944  Millions
Arbutus Biopharma Corp  11.92 $ 206.044  Millions$ 17.292  Millions
Anebulo Pharmaceuticals Inc   11.89 $ 8.521  Millions$ 0.717  Millions
Ovid Therapeutics Inc   11.70 $ 87.072  Millions$ 7.439  Millions
Xortx Therapeutics inc   11.69 $ 3.448  Millions$ 0.295  Millions
Sensei Biotherapeutics Inc   11.57 $ 72.013  Millions$ 6.226  Millions
Protagonist Therapeutics inc   11.51 $ 320.751  Millions$ 27.867  Millions
Ventyx Biosciences Inc   11.48 $ 300.819  Millions$ 26.208  Millions
Indaptus Therapeutics Inc   11.30 $ 15.964  Millions$ 1.413  Millions
Cormedix Inc   11.29 $ 86.587  Millions$ 7.671  Millions
Artelo Biosciences Inc   11.10 $ 10.225  Millions$ 0.921  Millions
Erasca Inc   11.10 $ 296.668  Millions$ 26.730  Millions
Anaptysbio Inc   11.03 $ 413.047  Millions$ 37.437  Millions
Lite Strategy Inc   10.95 $ 82.202  Millions$ 7.509  Millions
Opus Genetics Inc   10.84 $ 42.361  Millions$ 3.909  Millions
Ataibeckley Inc   10.77 $ 208.994  Millions$ 19.403  Millions

Date modified: 2026-06-22T14:32:36+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.